New insights into epigenetic modifications in heart failure

Area of Science:

• Cardiology
• Molecular Biology
• Genetics

Background:

• Heart failure (HF) is a complex clinical syndrome characterized by the heart's inability to pump blood effectively.
• Cardiac myocyte hypertrophy is a common hallmark of HF, driven by molecular reprogramming of gene expression.
• Understanding these molecular changes is crucial for developing novel HF therapies.

Purpose of the Study:

• To review the diverse functions of epigenetic modifications in the context of heart failure.
• To highlight the role of epigenetic changes as potential biomarkers for HF diagnosis and prognosis.
• To explore epigenetic modifications as therapeutic targets for heart failure.

Main Methods:

• Review of current scientific literature on epigenetics and heart failure.
• Discussion of key epigenetic mechanisms including DNA methylation, histone modifications, microRNAs, and long noncoding RNAs.
• Analysis of evidence supporting the role of epigenetics in HF pathogenesis and clinical application.

Main Results:

• Epigenetic modifications significantly influence gene expression reprogramming in cardiac myocytes during HF.
• Specific epigenetic marks are associated with hypertrophic changes and functional decline in the heart.
• Growing evidence supports the utility of epigenetic markers for early HF detection and outcome prediction.

Conclusions:

• Epigenetic modifications are integral to the molecular pathology of heart failure.
• Epigenetic biomarkers hold promise for improving HF diagnosis and prognosis.
• Targeting epigenetic pathways represents a potential new therapeutic strategy for managing heart failure.